biogen felzartamab - Search News

Biogen, felzartamab and TRANSCEND trial

Biogen initiates phase 3 study of felzartamab in kidney transplant patients

Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary membranous nephropathy, in 2025.

Clinical Trials Arena on MSN · 1d

Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.

Pharmabiz · 15h

Biogen begins TRANSCEND phase 3 study of felzartamab to treat late antibody-mediated rejection in kidney transplant patients

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST]

Zacks Investment Research on M… · 1d

BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant

Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated rejection (AMR).

Markets Insider · 2d

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a

Biogen announces initiation of dosing in TRANSCEND

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

pharmaphorum1d

Biogen shows its IgAN hand with felzartamab data

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Seeking Alpha29d

Biogen targets $15.25-$16.25 EPS for 2025 amid LEQEMBI growth and cost savings

Biogen remains focused on advancing its immunology and rare disease pipeline, including three Phase 3 trials for Felzartamab in 2025. Q4 non-GAAP diluted EPS was $3.44 compared to analysts ...

Nasdaq2d

Biogen Initiates Phase 3 TRANSCEND Study to Evaluate Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients

"I am pleased to see Biogen enroll the first patient in the Phase 3 TRANSCEND study of felzartamab in AMR and look forward to the trial’s continued enrollment.” TRANSCEND is a two-part ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results